United Therapeutics Corporation (UTHR) — Form 8-K: Current report

United Therapeutics Corporation filed a current report announcing a settlement agreement with Liquidia Technologies, Inc. and its subsidiaries to resolve multiple ongoing patent and antitrust litigations. Under the terms, Liquidia will pay United Therapeutics an aggregate of $330.4 million in damages, and United Therapeutics will pay Liquidia $10.0 million to resolve related litigation. Additionally, Liquidia agreed to amend its Yutrepia product label to remove the pulmonary hypertension associated with interstitial lung disease indication.